Global DNA Medicine Based on DNA Modification Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global DNA Medicine Based on DNA Modification Market Report, History and Forecast 2018-2034, Breakdown Data by Companies, Key Regions, Types and Application
Advanced Therapy Based on Gene is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
DNA Medicine Based on DNA Modification report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global DNA Medicine Based on DNA Modification market is projected to reach US$ 34850 million in 2033, increasing from US$ 9063 million in 2022, with the CAGR of 20.2% during the period of 2023 to 2033. Demand from Neurological Diseases and Cancer are the major drivers for the industry.
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global DNA Medicine Based on DNA Modification market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral
Non-viral
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the DNA Medicine Based on DNA Modification market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, DNA Medicine Based on DNA Modification introduction, etc. DNA Medicine Based on DNA Modification Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of DNA Medicine Based on DNA Modification market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
DNA Medicine Based on DNA Modification report published by MRAResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global DNA Medicine Based on DNA Modification market is projected to reach US$ 34850 million in 2033, increasing from US$ 9063 million in 2022, with the CAGR of 20.2% during the period of 2023 to 2033. Demand from Neurological Diseases and Cancer are the major drivers for the industry.
The advanced therapy based on gene market is driven by the potential to revolutionize healthcare by offering personalized and targeted treatments for genetic disorders and other diseases. Advanced therapy based on gene includes gene therapy, cell therapy, and gene editing techniques, which aim to modify or replace faulty genes to treat or cure diseases at the genetic level. The rise in the understanding of genetic mechanisms and advancements in biotechnology and genetic engineering contribute to market growth as these therapies hold promise for previously untreatable conditions. Moreover, increasing investment in research and clinical trials and the support from regulatory agencies for accelerated approval further boost the development and commercialization of advanced gene therapies. However, the market also faces challenges, including the complexity of manufacturing and delivering gene-based therapies, safety concerns related to viral vectors and off-target effects in gene editing, and high treatment costs. Additionally, addressing regulatory requirements and ensuring accessibility and affordability of advanced gene therapies can pose obstacles for broader adoption. To succeed, companies must focus on research and development to advance the safety and efficacy of gene-based therapies, collaborate with healthcare stakeholders to build robust infrastructure, and address the challenges to fully realize the transformative potential of advanced therapy based on gene in modern medicine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global DNA Medicine Based on DNA Modification market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Segment by Type
Viral
Non-viral
Segment by Application
Neurological Diseases
Cancer
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the DNA Medicine Based on DNA Modification market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2033).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2023.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, DNA Medicine Based on DNA Modification introduction, etc. DNA Medicine Based on DNA Modification Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12MRAResearch’s Conclusions of DNA Medicine Based on DNA Modification market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by MRAResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices